New study tracks bleeding risks in kids taking blood thinners
NCT ID NCT06278051
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at data from children under 18 in Japan who were prescribed either rivaroxaban or warfarin for blood clots. Researchers want to see how often major bleeding happens in real-world use. No new treatments are given—only existing medical records are reviewed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rivaroxaban (Xarelto)
What this could lead to
If successful, this study could provide a clearer picture of bleeding risks in children taking rivaroxaban for blood clots, helping doctors make safer prescribing decisions.
What could go wrong
This is an observational study that only looks at existing data, so it cannot prove cause and effect. Results may be limited by the quality of the records and may not apply to all children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bayer
Osaka, 530-0001, Japan
-
Many facilities
Multiple Locations, Japan